Singapore - engelsk - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - budesonide micronised - solution - 500 mcg/2 ml - budesonide micronised 500 mcg/2 ml

Singapore - engelsk - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - ticagrelor - tablet, film coated - 90 mg - ticagrelor 90 mg

Singapore - engelsk - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - budesonide - powder, metered - 100 mcg/dose - budesonide 100 mcg/dose

Singapore - engelsk - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - budesonide - powder, metered - 200 mcg/dose - budesonide 200 mcg/dose

Singapore - engelsk - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - atenolol; chlorthalidone - tablet, film coated - 50 mg - atenolol 50 mg; chlorthalidone 12.5 mg

Singapore - engelsk - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - goserelin acetate eqv peptide - injection - 3.6 mg/syringe - goserelin acetate eqv peptide 3.6 mg/syringe

Irland - engelsk - HPRA (Health Products Regulatory Authority)

ltt pharma limited - budesonide, formoterol fumarate dihydrate - powder for inhalation - 200/6 mcg/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics - adrenergics and other drugs for obstructive airway diseases - it is indicated in adults and adolescents aged 12 to 17 years for the regular treatment of asthma and for the symptomatic treatment of patients with severe copd

Irland - engelsk - HPRA (Health Products Regulatory Authority)

ltt pharma limited - budesonide, formoterol fumarate dihydrate - powder for inhalation - 400/12 mcg/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics - adrenergics and other drugs for obstructive airway diseases - it is indicated in adults and adolescents aged 12 to17 years for the regular treatment of asthma and for the symptomatic treatment of patients with severe copd

USA - engelsk - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - olaparib (unii: woh1jd9ar8) (olaparib - unii:woh1jd9ar8) - olaparib 50 mg - lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline brca -mutated (gbrcam ) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. select patients for therapy based on an fda-approved companion diagnostic for lynparza. none. risk summary based on findings in animals and its mechanism of action [see clinical pharmacology (12.1)] , lynparza can cause fetal harm when administered to a pregnant woman. there are no available data on lynparza use in pregnant women to inform the drug associated risk. in an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 400 mg twice daily [see data] . apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy. the estimated background risk of major birth d

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - water for injections -